BRIDGEWATER, New Jersey, June 26, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. („Synchronoss“) (NASDAQ: SNCR), ein weltweit führendes und innovatives Unternehmen im Bereich persönlicher [...] Read more »
Synchronoss obtient la certification du cadre de protection des données UE–États-Unis (DPF)
BRIDGEWATER, New Jersey, 26 juin 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (« Synchronoss ») (NASDAQ : SNCR), un innovateur et leader mondial des plateformes de cloud personnel, a [...] Read more »
Synchronoss Obtém Certificação de Estrutura de Privacidade de Dados UE-EUA
BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — A Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), líder global e inovadora em plataformas de nuvem pessoal para telecomunicações, [...] Read more »
Trident and Democratic Republic of Congo Sign Final Digital Identity Partnership and Launch Nationwide “DRCPass” Deployment
SINGAPORE and KINSHASA, June 25, 2025 (GLOBE NEWSWIRE) — Trident Digital Tech Holdings Ltd. (“Trident” or the “Company,” NASDAQ: TDTH), a Singapore–based catalyst for digital [...] Read more »
Synchronoss Achieves EU-U.S. Data Privacy Framework Certification
BRIDGEWATER, N.J., June 25, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (“Synchronoss”) (NASDAQ: SNCR), a global leader and innovator in personal cloud platforms for telecoms, today announced that [...] Read more »
OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in [...] Read more »
Accelerating Child Exploitation Investigations: Cellebrite Integrates Data from the National Center for Missing and Exploited Children (NCMEC)
TYSONS CORNER, Va., June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea & Emery Pharma Anunciam Colaboração Estratégica para Fornecer Estudos de Interação Medicamentosa Usando Rifampicina em Conformidade com o FDA
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — A Read more »
Fortrea et Emery Pharma annoncent une collaboration stratégique visant à mener des études sur les interactions médicamenteuses répondant aux normes de la FDA en utilisant la rifampicine
DURHAM, Caroline du Nord, 24 juin 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea und Emery Pharma kündigen strategische Zusammenarbeit zur Durchführung FDA-konformer Arzneimittelwechselwirkungsstudien mit Rifampin an
Durham, North Carolina, June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Fortrea & Emery Pharma Announce Strategic Collaboration to Deliver FDA Compliant Drug-Drug-Interaction Studies Using Rifampin
DURHAM, N.C., June 24, 2025 (GLOBE NEWSWIRE) — Read more »
Soluções Edge AI DA Próxima Geração Para o Mundo Real: Navegação Autônoma para Drones, Vigilância e Robótica
IRVINE, Califórnia, June 17, 2025 (GLOBE NEWSWIRE) — A Read more »
Edge-KI-Lösungen der nächsten Generation für die reale Welt: Autonome Navigation für Drohnen, Überwachung und Robotik
IRVINE, Kalifornien, June 17, 2025 (GLOBE NEWSWIRE) — Read more »
Solutions Edge AI de pointe pour le monde réel : navigation autonome pour drones, surveillance et robotique
IRVINE, Californie, 17 juin 2025 (GLOBE NEWSWIRE) — Read more »
Next-Gen Edge AI Solutions for the Real World: Autonomous Navigation for Drones, Surveillance and Robotics
IRVINE, Calif., June 17, 2025 (GLOBE NEWSWIRE) — Read more »